Lab
Augustus Labs LLC
Augustus Labs LLC was paid $3.73M by Medicaid between Nov 2020 and Dec 2024, across 97 billing codes. Its largest line is 87481, — 13% of everything it billed.
33Billing provider infoAUGUSTUS LABS LLC
DOWNERS GROVE, IL 60515
DOWNERS GROVE, IL 60515
33aNPI1477173847assigned 04/25/2020
33bProvider typeClinical Medical Laboratory
28Total paid$3.73M
24GClaims152,338
24DCodes billed97
24AFirst – last monthNov 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#44 of 235
Median peer was paid$123K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 162 | $10K | |
| 2021 | 18,387 | $299K | |
| 2022 | 14,532 | $400K | |
| 2023 | 26,967 | $643K | |
| 2024incomplete | 92,290 | $2.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87481 | 13% | 3,656 | 3,016 | $473K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 12% | 9,505 | 3,106 | $452K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 12% | 895 | 833 | $434K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 6.5% | 3,369 | 2,811 | $244K |
| 87581 | 3.9% | 4,125 | 3,468 | $146K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.7% | 3,874 | 3,215 | $136K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.6% | 2,980 | 2,443 | $135K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.5% | 8,415 | 2,656 | $129K |
| 87500 | 3.3% | 4,847 | 3,951 | $125K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.9% | 7,350 | 6,027 | $109K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.9% | 1,176 | 963 | $109K |
| 87653 | 2.9% | 3,022 | 2,515 | $108K |
85 more codes
| 87541 | 2.8% | 2,961 | $105K | |
| 84443 | Thyroid stimulating hormone (TSH) | 2.4% | 6,511 | $90K |
| 82607 | 2.0% | 6,737 | $73K | |
| 80053 | Comprehensive metabolic panel | 1.6% | 7,593 | $59K |
| 80061 | Lipid panel | 1.5% | 8,137 | $56K |
| 82746 | 1.3% | 4,698 | $47K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 6,974 | $42K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 7,969 | $41K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,215 | $37K |
| 86141 | <1% | 2,845 | $36K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 751 | $31K |
| 87641 | <1% | 826 | $28K | |
| 82728 | <1% | 3,672 | $27K | |
| 87486 | <1% | 695 | $27K | |
| 84439 | <1% | 3,425 | $26K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 993 | $24K |
| 87640 | <1% | 643 | $24K | |
| 83540 | <1% | 3,445 | $18K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 496 | $18K |
| 87634 | <1% | 341 | $17K | |
| 87400 | <1% | 1,040 | $16K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 532 | $16K |
| 87498 | <1% | 388 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 775 | $14K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 388 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 403 | $14K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 403 | $14K |
| 81514 | <1% | 80 | $13K | |
| 87563 | <1% | 736 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,495 | $12K |
| 84153 | <1% | 795 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,181 | $9K |
| 86480 | <1% | 200 | $9K | |
| 83550 | <1% | 1,355 | $9K | |
| 87999 | <1% | 78 | $9K | |
| 83735 | <1% | 1,507 | $8K | |
| 80076 | <1% | 903 | $8K | |
| 86706 | <1% | 638 | $7K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 129 | $7K |
| 84480 | <1% | 794 | $6K | |
| 86735 | <1% | 528 | $6K | |
| 83880 | <1% | 188 | $5K | |
| 80074 | <1% | 112 | $5K | |
| 84436 | <1% | 1,015 | $5K | |
| 82570 | <1% | 1,131 | $4K | |
| 86762 | <1% | 532 | $4K | |
| 85027 | <1% | 954 | $4K | |
| 82043 | <1% | 1,158 | $4K | |
| 86765 | <1% | 520 | $4K | |
| 86592 | <1% | 1,055 | $4K | |
| 86038 | <1% | 261 | $3K | |
| 83519 | <1% | 263 | $3K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 26 | $3K |
| 87800 | <1% | 103 | $3K | |
| 81003 | <1% | 1,439 | $2K | |
| 87631 | <1% | 26 | $2K | |
| 86803 | <1% | 180 | $2K | |
| 86200 | <1% | 156 | $2K | |
| 83001 | <1% | 121 | $2K | |
| 84403 | <1% | 74 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 194 | $2K |
| 86431 | <1% | 247 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 66 | $1K |
| 83002 | <1% | 105 | $1K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 57 | $1K |
| 82378 | <1% | 62 | $1K | |
| 84702 | <1% | 110 | $1K | |
| 85652 | <1% | 408 | $988.82 | |
| 84481 | <1% | 95 | $968.32 | |
| 84156 | <1% | 410 | $889.61 | |
| 84550 | <1% | 265 | $847.77 | |
| 84479 | <1% | 117 | $531.02 | |
| 82172 | <1% | 45 | $525.87 | |
| 85610 | <1% | 140 | $463.76 | |
| 84146 | <1% | 34 | $410.19 | |
| 86304 | <1% | 19 | $406.90 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $198.64 |
| 83655 | <1% | 14 | $148.24 | |
| 84703 | <1% | 27 | $142.15 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 18 | $127.58 |
| 83090 | <1% | 14 | $123.22 | |
| 83721 | <1% | 16 | $102.56 | |
| 85730 | <1% | 31 | $97.24 | |
| 83695 | <1% | 14 | $76.01 | |
| 80050 | General health panel | <1% | 12 | $12.93 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNIKNAM, JABER (OWNER)